TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 27344439

Group type: EXPERIMENTAL
Intervention: Dalteparin (subcutaneous 200 IU/kg once daily during month 1, followed by 150 IU/kg once daily for months 2-6)
Number of subjects: 676

Group type: COMPARATOR
Intervention: Vitamin K antagonist (VKA) (once daily for 6 months, with initial overlapping subcutaneous dalteparin 200 IU/kg once daily for ≥5 days until INR was 2.0-3.0 for 2 consecutive days)
Number of subjects: 676

Group type: EXPERIMENTAL
Intervention: Dalteparin
Number of subjects: 676

Group type: COMPARATOR
Intervention: VKA
Number of subjects: 676
Study: 24873096

Group type: EXPERIMENTAL
Intervention: Proximal turn‐down group
Number of subjects: 48

Group type: COMPARATOR
Intervention: Palmaris longus tendon graft group
Number of subjects: 48
Study: 22551881

Group type: EXPERIMENTAL
Intervention: Calcium-vitamin D3 fixed combination
Number of subjects: 610

Group type: EXPERIMENTAL
Intervention: Calcium plus vitamin D3 separate combination
Number of subjects: 610

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 610
Study: 20861210

Group type: EXPERIMENTAL
Intervention: Polyphenols (PP) 50 mg
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Polyphenols (PP) 200 mg
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Whole bean porridge with PP and PA removal
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: PP removal from dephytinized porridge
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Dephytinization in the absence of PP
Number of subjects: 17
Study: 19073970

Group type: EXPERIMENTAL
Intervention: First-line chemotherapy
Number of subjects: 527
Study: 16387150

Group type: EXPERIMENTAL
Intervention: DAC-7 (daunorubicine + cytarabine + cladribine)
Number of subjects: 66

Group type: COMPARATOR
Intervention: DA-7 (daunorubicine + cytarabine without cladribine)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: DAC-7
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: DAC-7 and DA-7
Number of subjects: 66
Study: 12819407

Group type: EXPERIMENTAL
Intervention: Preoperative chemotherapy (group 1, G1)
Number of subjects: 83

Group type: COMPARATOR
Intervention: No chemotherapy (group 2, G2)
Number of subjects: 83
Study: 10625567

Group type: EXPERIMENTAL
Intervention: EMLA (topical analgesia cream)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 7965421

Group type: EXPERIMENTAL
Intervention: Mixed diet (group MD) containing rice, chicken, carrots, beans, and vegetable oil
Number of subjects: 87

Group type: COMPARATOR
Intervention: Lactose-free, soy protein isolate formula (group SF)
Number of subjects: 87
Study: 2888658

Group type: EXPERIMENTAL
Intervention: 10 mg mifentidine
Number of subjects: 10
Study: 31532004

Group type: EXPERIMENTAL
Intervention: Volume-based feeding protocol (VP)
Number of subjects: 227

Group type: COMPARATOR
Intervention: Conventional hourly rate method (CM)
Number of subjects: 227
Study: 29466786

Group type: EXPERIMENTAL
Intervention: Vitamin D3 50,000 IU every 2 weeks for 6 months
Number of subjects: 58

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 58
Study: 26516810

Group type: EXPERIMENTAL
Intervention: Anticholinergic (AC) treatment
Number of subjects: 243

Group type: COMPARATOR
Intervention: Placebo (P) treatment
Number of subjects: 243
Study: 27371428

Group type: EXPERIMENTAL
Intervention: ICG-PDT (Indocyanine green photodynamic therapy) with 0.1% ICG lotion applied for 30 minutes and long pulse diode laser, 3 treatments over 2 weeks
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: ICG-PDT (Indocyanine green photodynamic therapy) with 0.1% ICG lotion applied for 30 minutes and long pulse diode laser, 5 treatments over 2 weeks
Number of subjects: 47
Study: 23896389

Group type: EXPERIMENTAL
Intervention: Caspase-3 and caspase-9 expression in Group 3 (DM and DR)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Caspase-3 and caspase-9 expression in Group 2 (DM without DR)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Caspase-3 and caspase-9 expression in Group 1 (no DM)
Number of subjects: 60
Study: 21764028

Group type: EXPERIMENTAL
Intervention: Baseline TIMI grade 3 flow
Number of subjects: 5332

Group type: EXPERIMENTAL
Intervention: Final TIMI grade 3 flow
Number of subjects: 5332
Study: 18849616

Group type: EXPERIMENTAL
Intervention: Cluster SIT (14 injections of house dust mite allergen within 6 weeks)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Classic SIT (14 injections of house dust mite allergen within 14 weeks)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Cluster SIT
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Cluster SIT and Classic SIT
Number of subjects: 34
Study: 17093147

Group type: EXPERIMENTAL
Intervention: 11trans-18:1 and 12trans-18:1 supplementation (3.0 g each per day for 6 weeks)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control oil free of trans fatty acids and conjugated linoleic acids
Number of subjects: 24
Study: 15269141

Group type: EXPERIMENTAL
Intervention: hTERT:540-548 peptide emulsified in incomplete Freund's adjuvant
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: hTERT:540-548 peptide
Number of subjects: 14
Study: 11692118

Group type: EXPERIMENTAL
Intervention: Intramuscular injection of epinephrine into the thigh
Number of subjects: 0

Group type: COMPARATOR
Intervention: Intramuscular injection of epinephrine into the upper arm
Number of subjects: 0

Group type: COMPARATOR
Intervention: Subcutaneous injection of epinephrine into the upper arm
Number of subjects: 0
Study: 10554767

Group type: EXPERIMENTAL
Intervention: IUGR pregnancies
Number of subjects: 19

Group type: COMPARATOR
Intervention: Control pregnancies
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Lactate dehydrogenase release
Number of subjects: 19
Study: 7646942

Group type: EXPERIMENTAL
Intervention: Ginger taken prior to 8‐MOP
Number of subjects: 0

Group type: COMPARATOR
Intervention: 8‐MOP without ginger
Number of subjects: 0
Study: 2816804

Group type: EXPERIMENTAL
Intervention: Nutrition counseling (intervention group)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 73792

Group type: EXPERIMENTAL
Intervention: Cimetidine
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study: 31553500

Group type: EXPERIMENTAL
Intervention: Resource loss
Number of subjects: 312

Group type: EXPERIMENTAL
Intervention: Daily stressors
Number of subjects: 312

Group type: EXPERIMENTAL
Intervention: Number of relocation experiences
Number of subjects: 312

Group type: EXPERIMENTAL
Intervention: Psychosocial resource loss
Number of subjects: 312

Group type: EXPERIMENTAL
Intervention: Male sex
Number of subjects: 312

Group type: EXPERIMENTAL
Intervention: Lower educational status
Number of subjects: 312
Study: 31077124

Group type: EXPERIMENTAL
Intervention: Prone position
Number of subjects: 40

Group type: COMPARATOR
Intervention: Supine position
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Supine and prone positions
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Distance from left common iliac artery to anterior contour of L4/L5 intervertebral disc
Number of subjects: 40
Study: 28888618

Group type: EXPERIMENTAL
Intervention: Individualized feedback intervention to doctors; patients rated their perception of the doctor's quality of care using an 8-question feedback card.
Number of subjects: 379

Group type: COMPARATOR
Intervention: Control group with no feedback intervention.
Number of subjects: 379
Study: 25542920

Group type: EXPERIMENTAL
Intervention: High levels of exercise at baseline
Number of subjects: 342

Group type: COMPARATOR
Intervention: Low levels of exercise at baseline
Number of subjects: 342

Group type: EXPERIMENTAL
Intervention: Initial changes in exercise
Number of subjects: 342
Study: 23064476

Group type: EXPERIMENTAL
Intervention: 5-mg of alendronate and 0.5-µg of calcitriol (Maxmarvil®)
Number of subjects: 98

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 98
Study: 22141229

Group type: EXPERIMENTAL
Intervention: Zirconia-based FDPs
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Zirconia frameworks
Number of subjects: 45

Group type: COMPARATOR
Intervention: Periodontal health
Number of subjects: 45
Study: 19920054

Group type: EXPERIMENTAL
Intervention: Ferric carboxymaltose (200 mg intravenous iron)
Number of subjects: 459

Group type: COMPARATOR
Intervention: Saline (placebo)
Number of subjects: 459
Study: 16491287

Group type: EXPERIMENTAL
Intervention: Calcium- and vitamin D3-fortified milk (400 ml/day providing 1000 mg calcium and 800 IU vitamin D3)
Number of subjects: 167

Group type: COMPARATOR
Intervention: Control group (no additional milk)
Number of subjects: 167
Study: 12760893

Group type: EXPERIMENTAL
Intervention: Telithromycin (800 mg once daily)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Amoxicillin‐clavulanic acid (1 g of amoxicillin and 125 mg of clavulanic acid 3 times daily)
Number of subjects: 0
Study: 10690692

Group type: EXPERIMENTAL
Intervention: New low-dose warfarin induction regimen
Number of subjects: 120

Group type: COMPARATOR
Intervention: Modified Fennerty regimen
Number of subjects: 120
Study: 8986520

Group type: EXPERIMENTAL
Intervention: Photograph of chocolate
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Actual chocolate
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 0
Study: 8489296

Group type: EXPERIMENTAL
Intervention: Idarubicin 10 mg/m2
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Idarubicin 12 mg/m2
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Idarubicin 15 mg/m2
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Idarubicin in acute myelogenous leukemia
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Idarubicin in chronic myelogenous leukemia in blast crisis
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Idarubicin in patients with prior anthracycline therapy
Number of subjects: 47
Study: 3813060

Group type: EXPERIMENTAL
Intervention: 0.15 mg/kg of intramuscular morphine 30‐60 min before induction
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: 1 microgram/kg of IV fentanyl 10 min after skin incision
Number of subjects: 81

Group type: COMPARATOR
Intervention: halothane
Number of subjects: 81

Group type: COMPARATOR
Intervention: isoflurane
Number of subjects: 81

Group type: COMPARATOR
Intervention: enflurane
Number of subjects: 81
Study: 29948896

Group type: EXPERIMENTAL
Intervention: hyperlipidic-hypoglycemic diet
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: fasting longer than 12 hours
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: fasting associated with intravenous heparin
Number of subjects: 10
Study: 29126612

Group type: EXPERIMENTAL
Intervention: Desflurane
Number of subjects: 61

Group type: COMPARATOR
Intervention: TIVA (Propofol)
Number of subjects: 61
Study: 27567897

Group type: EXPERIMENTAL
Intervention: Intensive medical therapy (IMT)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Control group (healthy subjects)
Number of subjects: 13
Study: 25093868

Group type: EXPERIMENTAL
Intervention: Hochuekkito (oral) for 24 weeks
Number of subjects: 18

Group type: COMPARATOR
Intervention: Control group (no Hochuekkito) for 24 weeks
Number of subjects: 18
Study: 22382523

Group type: EXPERIMENTAL
Intervention: Combined treatment group (CMG) treated with Chinese herbs for supplementing qi, nourishing yin and activating blood circulation, besides Western medicine treatment.
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Combined treatment group (CMG)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Western medicine group (WMG)
Number of subjects: 100
Study: 20669671

Group type: EXPERIMENTAL
Intervention: Chinese Medicine internal-external combined therapy (ipratropium bromide aerosol, ambroxol hydrochloride, Chinese recipe, acupoint sticking with Xiaochuan Plaster)
Number of subjects: 178

Group type: COMPARATOR
Intervention: Atrovent Metered Dose Inhalation, oral Mucosolvan, Bailing Capsule, acupoint sticking with dummy plaster (Control)
Number of subjects: 178
Study: 18772061

Group type: EXPERIMENTAL
Intervention: Atorvastatin 80 mg
Number of subjects: 2986

Group type: COMPARATOR
Intervention: Pravastatin 40 mg
Number of subjects: 2986
Study: 15944842

Group type: EXPERIMENTAL
Intervention: Improved metabolic control (optimisation period for 6-12 months)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: ACE inhibitors (for two years)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Sequential use of improved metabolic control and ACE inhibitor therapy
Number of subjects: 44
Study: 12638108

Group type: EXPERIMENTAL
Intervention: PREHAB program
Number of subjects: 94
Study: 10189970

Group type: EXPERIMENTAL
Intervention: Low-intensity long-term follow-up protocol (case monitoring) for alcohol abusers
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not specified
Number of subjects: 0
Study: 8898511

Group type: EXPERIMENTAL
Intervention: High Intensity (HI) exercise at 65% VO2max for 30 minutes
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Moderate Intensity (MI) exercise at approximately 55% VO2max
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Low Intensity (LI) exercise at approximately 45% VO2max
Number of subjects: 8

Group type: COMPARATOR
Intervention: Comparison of HI, MI, and LI
Number of subjects: 8
Study: 1829388

Group type: EXPERIMENTAL
Intervention: Percutaneous transluminal renal angioplasty (PTRA)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Reconstructive surgery
Number of subjects: 37
Study: 6294433

Group type: EXPERIMENTAL
Intervention: Naloxone (opiate receptor blockade)
Number of subjects: 0
Study: 30382806

Group type: EXPERIMENTAL
Intervention: Walking+supplement
Number of subjects: 4

Group type: COMPARATOR
Intervention: Walking
Number of subjects: 4

Group type: COMPARATOR
Intervention: Low-intensity activity with complex cognitive demands (dancing)
Number of subjects: 4

Group type: COMPARATOR
Intervention: Active control
Number of subjects: 4
Study: 26748734

Group type: EXPERIMENTAL
Intervention: Nemonoxacin 500 mg
Number of subjects: 192

Group type: EXPERIMENTAL
Intervention: Nemonoxacin 750 mg
Number of subjects: 192

Group type: COMPARATOR
Intervention: Levofloxacin 500 mg
Number of subjects: 192

Group type: EXPERIMENTAL
Intervention: Nemonoxacin 500 mg and 750 mg
Number of subjects: 192
Study: 25811246

Group type: EXPERIMENTAL
Intervention: Self-ligating bracket system (3M SmartClip™)
Number of subjects: 138

Group type: COMPARATOR
Intervention: Conventional bracket system (3M Victory™)
Number of subjects: 138
Study: 24891576

Group type: COMPARATOR
Intervention: No drainage (group A)
Number of subjects: 575

Group type: EXPERIMENTAL
Intervention: Wound drainage with ABT drain for six hours (group B)
Number of subjects: 575

Group type: EXPERIMENTAL
Intervention: Wound drainage with ABT drain for 24 hours (group C)
Number of subjects: 575

Group type: EXPERIMENTAL
Intervention: All groups (including transfused patients)
Number of subjects: 575

Group type: EXPERIMENTAL
Intervention: THR patients
Number of subjects: 575

Group type: EXPERIMENTAL
Intervention: TKR patients
Number of subjects: 575
Study: 21497935

Group type: EXPERIMENTAL
Intervention: Type 2 diabetes patients
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Type 2 diabetes patients with HbA(1c) < 7.0% (53 mmol/mol)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 60
Study: 19017418

Group type: EXPERIMENTAL
Intervention: Diet/Probiotics (Lactobacillus rhamnosus GG and Bifidobacterium lactis Bb12)
Number of subjects: 256

Group type: COMPARATOR
Intervention: Diet/Placebo
Number of subjects: 256

Group type: COMPARATOR
Intervention: Control/Placebo
Number of subjects: 256
Study: 17351155

Group type: EXPERIMENTAL
Intervention: Orlistat 120 mg tid for 10 days combined with a low-calorie diet
Number of subjects: 32

Group type: COMPARATOR
Intervention: Low-calorie diet only (control group)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Orlistat group
Number of subjects: 32

Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 32
Study: 15068431

Group type: EXPERIMENTAL
Intervention: Sub-Tenon infiltration with 3 mL of bupivacaine 0.50%
Number of subjects: 100

Group type: COMPARATOR
Intervention: Classical analgesic drugs (control group)
Number of subjects: 100
Study: 11399986

Group type: EXPERIMENTAL
Intervention: Information/motivation program with free distribution of female and male condoms
Number of subjects: 1929

Group type: COMPARATOR
Intervention: Male condoms and related information (control)
Number of subjects: 1929
Study: 9442428

Group type: EXPERIMENTAL
Intervention: n-3 PUFA (fish oil: 30% n-3 PUFA)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Placebo (olive oil containing only 1% of n-3 PUFA)
Number of subjects: 37
Study: 7835813

Group type: EXPERIMENTAL
Intervention: Abdomino-pelvic radiation therapy (APRT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: 32P
Number of subjects: 0
Study: 2822723

Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin
Number of subjects: 20

Group type: COMPARATOR
Intervention: Albumin (Control)
Number of subjects: 20
Study: 31925268

Group type: EXPERIMENTAL
Intervention: Sevoflurane general anesthesia
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Sevoflurane-plus-ketamine general anesthesia
Number of subjects: 12
Study: 29441841

Group type: EXPERIMENTAL
Intervention: Platelet transfusion with standard care
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard care alone
Number of subjects: 0
Study: 27276742

Group type: COMPARATOR
Intervention: Moringa Oleifera (MO) leaf at 0 g
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Moringa Oleifera (MO) leaf at 1 g
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Moringa Oleifera (MO) leaf at 2 g
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Moringa Oleifera (MO) leaf at 4 g
Number of subjects: 10

Group type: COMPARATOR
Intervention: Moringa Oleifera (MO) leaf at 4 g vs baseline (0 g)
Number of subjects: 10
Study: 24364856

Group type: EXPERIMENTAL
Intervention: Psychological distancing
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Reinterpretation
Number of subjects: 3

Group type: COMPARATOR
Intervention: No-regulation control
Number of subjects: 3
Study: 22664649

Group type: EXPERIMENTAL
Intervention: Coaching intervention with trained lay coaches promoting asthma management strategies
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: More coach contacts overall
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Multivariable models adjusting for characteristics of participants and coaching process
Number of subjects: 120
Study: 20379731

Group type: EXPERIMENTAL
Intervention: GnRH antagonist
Number of subjects: 95

Group type: COMPARATOR
Intervention: GnRH agonist
Number of subjects: 95
Study: 18536623

Group type: EXPERIMENTAL
Intervention: Hepatitis A vaccine administered concomitantly with pneumococcal conjugate vaccine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Hepatitis A vaccine administered separately
Number of subjects: 0
Study: 15813838

Group type: EXPERIMENTAL
Intervention: Antibiotic combination therapy (amoxicillin, tetracycline, and metronidazole for 2 weeks)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Antibiotic combination therapy
Number of subjects: 20

Group type: COMPARATOR
Intervention: No-antibiotics group
Number of subjects: 20
Study: 12551964

Group type: EXPERIMENTAL
Intervention: 11.25 degrees step increments of visual feedback rotation, every 45 trials (up to a total of 90 degrees)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 90 degrees rotation from the onset of exposure
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Gradual distortion
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Removal of the distortion
Number of subjects: 0
Study: 10395431

Group type: EXPERIMENTAL
Intervention: Active chiropractic spinal manipulation (SMT)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo chiropractic spinal manipulation (sham SMT)
Number of subjects: 22
Study: 8893580

Group type: EXPERIMENTAL
Intervention: Intraoperative autologous donation (IAD)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control group (no IAD)
Number of subjects: 90
Study: 2068243

Group type: EXPERIMENTAL
Intervention: MMR vaccine
Number of subjects: 420

Group type: COMPARATOR
Intervention: Measles vaccine
Number of subjects: 420
Study: 6661383

Group type: EXPERIMENTAL
Intervention: Brotizolam 0.25 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Brotizolam 0.50 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 31102142

Group type: EXPERIMENTAL
Intervention: BVDV infection in ICC
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Quantitative real-time PCR (qRT-PCR) validation of DEGs
Number of subjects: 0
Study: 29950801

Group type: EXPERIMENTAL
Intervention: Indocyanine green (ICG) 7.5 mg intravenous dose
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Monopolar device
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Ultrasonic device
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Barbed sutures
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Nonbarbed sutures
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Longer instrument activation times
Number of subjects: 20
Study: 27651039

Group type: EXPERIMENTAL
Intervention: Eplerenone
Number of subjects: 50

Group type: COMPARATOR
Intervention: Hydrochlorothiazide (HCTZ)
Number of subjects: 50
Study: 24577124

Group type: EXPERIMENTAL
Intervention: Rivaroxaban 10, 15, or 20 mg once daily
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Dabigatran 110 or 150 mg twice daily
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Rivaroxaban and Dabigatran
Number of subjects: 42
Study: 22686551

Group type: EXPERIMENTAL
Intervention: Telephone-based cognitive-behavioral therapy (CBT)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Face-to-face cognitive-behavioral therapy (CBT)
Number of subjects: 14
Study: 20082712

Group type: EXPERIMENTAL
Intervention: 7.5% hypertonic saline in combination with 6% dextran‐70 (HSD)
Number of subjects: 65

Group type: COMPARATOR
Intervention: 0.9% normal saline (NS)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Control group (25 healthy subjects)
Number of subjects: 65
Study: 17565563

Group type: EXPERIMENTAL
Intervention: Brief alcohol intervention (BAI)
Number of subjects: 987

Group type: COMPARATOR
Intervention: Control group with screening and assessment
Number of subjects: 987

Group type: COMPARATOR
Intervention: Control group with screening only
Number of subjects: 987

Group type: COMPARATOR
Intervention: All groups (BAI and controls)
Number of subjects: 987
Study: 15632210

Group type: EXPERIMENTAL
Intervention: Detection of intracellular SH2D1A protein using four-color flow cytometry in patients with XLP
Number of subjects: 15

Group type: COMPARATOR
Intervention: Detection of intracellular SH2D1A protein in carriers of SH2D1A mutations
Number of subjects: 15

Group type: COMPARATOR
Intervention: Detection of intracellular SH2D1A protein in males with clinical syndromes consistent with XLP
Number of subjects: 15